#obesity drugs

A nationwide self-controlled study in Denmark found people with asthma who started GLP-1 drugs saw fewer exacerbations and less reliever inhaler use over the following year.

A new episode of STAT News’ Readout LOUD podcast centers on Seaport Therapeutics’ IPO, battles over obesity pills, and the political troubles surrounding FDA Commissioner Marty Makary.

Novo Nordisk used its first-quarter update to highlight early uptake for its Wegovy pill as it navigates pricing pressure, payer dynamics, and fresh competition from Eli Lilly.

CMS has indefinitely delayed a Medicare pilot focused on obesity medication coverage after insurance plans signaled they were not ready to participate.

The FDA has asked Eli Lilly for additional data on its obesity pill Foundayo as the agency evaluates potential risks related to major cardiovascular events and liver damage.

Novo Nordisk is navigating two departures at once, including the retirement of GLP-1 pioneer Lotte Bjerre Knudsen and the loss of an obesity leader to Boehringer Ingelheim.

A weekly Endpoints roundup points to a biotech market closing the quarter with bolt-on acquisitions, obesity-program volatility, and a Sanofi partnership in T-cell engager research.

Structure Therapeutics reports encouraging Phase 2 results for its oral GLP-1 receptor agonist, advancing a pill-form alternative to injectable weight-loss and diabetes drugs.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.